The founding CEO of Darmiyan, Padideh is a 2020 Fortune 40 under 40 global healthcare leader/ influencer, a 2018 TEDMED Hive Innovator who is listed by Healthcare Tech Report in Top 25 Women Leaders in Biotech for 2021, and the 2023 innovation award recipient of KTH, the Swedish Royal Institute of Technology. Under her leadership, Darmiyan received funding support by Eisai, IT-Farm and Y-Combinator and secured US and Japanese patents for BrainSee, the first medical AI-powered SaaS for Alzheimer’s disease diagnosis. BrainSee received FDA breakthrough device designation in May 2021.

Padideh has been leading the company since founding it in 2014, taking the technology through multiple stages of development, from conception to a functioning product (BrainSee), which helped the company achieve widespread recognition in the biomedical and life science communities, including being a 2021 UCSF Health Awards finalist. In Persian Darmiyan means “in-between,” reflecting how the company’s technology decodes the space between our cells to illuminate the status of brain health long before any signs of memory loss.

Padideh is well-regarded globally for her expertise in geometrical modeling of brain tissue microstructure, her cross-cultural understanding of brain health and her visionary approach to complex problems. Prior to founding Darmiyan, she was an Adjunct Assistant Professor at New York University School of Medicine, where she collaborated with Professor Charles Nicholson, the pioneer of brain microstructure modeling. Padideh got her PhD in biological physics from Royal Institute of Technology (KTH) in Stockholm, Sweden in 2010. Her PhD thesis entitled “Biophysical mechanisms underlying cellular homeostasis” laid a foundation for the company’s novel work creating a virtual microscope of the brain. In her free time Padideh enjoys teaching Persian classical music.